Physician profile
Anthony V Rocha
NPI 1386655710
$4,319.01
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,645 · 2020: $427 · 2021: $1,225 · 2022: $1,022.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $992.38 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $874.99 | 2019-2022 | |
| Pfizer INC. | $372.45 | 2019-2022 | |
| Indivior INC. | $255.49 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $243.49 | 2019-2022 | |
| Abbvie INC. | $220.33 | 2021-2022 | |
| Novo Nordisk INC | $170.49 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $143.13 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $143.11 | 2021 | |
| Ironwood Pharmaceuticals, INC | $140.86 | 2019-2020 | |
| Lilly USA, LLC | $140.15 | 2019-2022 | |
| Allergan, INC. | $131.29 | 2019-2020 | |
| Astellas Pharma US INC | $124.96 | 2019 | |
| Amgen INC. | $124.85 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $77.66 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $46.50 | 2021 | |
| Merck Sharp & Dohme LLC | $31.28 | 2019-2022 | |
| Glaxosmithkline, LLC. | $20.91 | 2022 | |
| Eisai INC. | $14.69 | 2020 | |
| Bausch Health US, LLC | $14.04 | 2022 | |
| Orexo US, INC. | $13.76 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.14 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.06 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Rocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.